These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 30614347)

  • 21. The current status of therapy for symptomatic late-onset hypogonadism with transdermal testosterone gel.
    Ebert T; Jockenhövel F; Morales A; Shabsigh R
    Eur Urol; 2005 Feb; 47(2):137-46. PubMed ID: 15661407
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Testosterone treatment in the aging male: myth or reality?
    Nigro N; Christ-Crain M
    Swiss Med Wkly; 2012; 142():w13539. PubMed ID: 22430839
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Androgen replacement after curative radical prostatectomy for prostate cancer in hypogonadal men.
    Kaufman JM; Graydon RJ
    J Urol; 2004 Sep; 172(3):920-2. PubMed ID: 15310998
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Low testosterone levels are related to poor prognosis factors in men with prostate cancer prior to treatment.
    García-Cruz E; Piqueras M; Huguet J; Peri L; Izquierdo L; Musquera M; Franco A; Alvarez-Vijande R; Ribal MJ; Alcaraz A
    BJU Int; 2012 Dec; 110(11 Pt B):E541-6. PubMed ID: 22584031
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Variations in circulating sex steroid levels in metastatic prostate cancer patients with combined androgen blockade: observation and implication.
    Qin X; Zhang H; Ye D; Yao X; Zhang S; Dai B
    Andrology; 2013 May; 1(3):512-6. PubMed ID: 23536478
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Testosterone treatment is not associated with increased risk of prostate cancer or worsening of lower urinary tract symptoms: prostate health outcomes in the Registry of Hypogonadism in Men.
    Debruyne FM; Behre HM; Roehrborn CG; Maggi M; Wu FC; Schröder FH; Jones TH; Porst H; Hackett G; Wheaton OA; Martin-Morales A; Meuleman E; Cunningham GR; Divan HA; Rosen RC;
    BJU Int; 2017 Feb; 119(2):216-224. PubMed ID: 27409523
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Is testosterone a friend or a foe of the prostate?
    Jannini EA; Gravina GL; Morgentaler A; Morales A; Incrocci L; Hellstrom WJ
    J Sex Med; 2011 Apr; 8(4):946-55. PubMed ID: 21457469
    [TBL] [Abstract][Full Text] [Related]  

  • 28. One year follow-up study of the association between chemical castration, sex hormones, beta-amyloid, memory and depression in men.
    Almeida OP; Waterreus A; Spry N; Flicker L; Martins RN
    Psychoneuroendocrinology; 2004 Sep; 29(8):1071-81. PubMed ID: 15219659
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Serum inhibin--not a cause of low testosterone levels in hypogonadal prostate cancer?
    Lackner JE; Maerk I; Koller A; Bieglmayer C; Marberger M; Kratzik C; Schatzl G
    Urology; 2008 Nov; 72(5):1121-4. PubMed ID: 18407338
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dynamic Patterns of Testosterone Levels in Individuals and Risk of Prostate Cancer among Hypogonadal Men: A Longitudinal Study.
    Xu X; Zhang X; Zhong Y; Saad F; Perez-Patron MJ; Haider K; Haider A
    J Urol; 2018 Feb; 199(2):465-473. PubMed ID: 28941925
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of testosterone replacement on serotonin levels in the prostate and plasma in a murine model of hypogonadism.
    Mota P; Barbosa-Martins J; Moura RS; Lima E; Miranda A; Correia-Pinto J; Carvalho-Dias E
    Sci Rep; 2020 Sep; 10(1):14688. PubMed ID: 32895458
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Testosterone and prostate cancer: what are the risks for middle-aged men?
    Morgentaler A
    Urol Clin North Am; 2011 May; 38(2):119-24. PubMed ID: 21621078
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Testosterone administration to men with testosterone deficiency syndrome after external beam radiotherapy for localized prostate cancer: preliminary observations.
    Morales A; Black AM; Emerson LE
    BJU Int; 2009 Jan; 103(1):62-4. PubMed ID: 18671790
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The relationship between total and free serum testosterone and the risk of prostate cancer and tumour aggressiveness.
    Morote J; Ramirez C; Gómez E; Planas J; Raventós CX; de Torres IM; Catalán R
    BJU Int; 2009 Aug; 104(4):486-9. PubMed ID: 19220251
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Testosterone therapy in men with prostate cancer: scientific and ethical considerations.
    Morgentaler A
    J Urol; 2013 Jan; 189(1 Suppl):S26-33. PubMed ID: 23234627
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prevalence of prostate cancer among hypogonadal men with prostate-specific antigen levels of 4.0 ng/mL or less.
    Morgentaler A; Rhoden EL
    Urology; 2006 Dec; 68(6):1263-7. PubMed ID: 17169647
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Low serum testosterone levels are associated with positive surgical margins in radical retropubic prostatectomy: hypogonadism represents bad prognosis in prostate cancer.
    Teloken C; Da Ros CT; Caraver F; Weber FA; Cavalheiro AP; Graziottin TM
    J Urol; 2005 Dec; 174(6):2178-80. PubMed ID: 16280759
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Suppression of plasma androgens by spironolactone in castrated men with carcinoma of the prostate.
    Walsh PC; Siiteri PK
    J Urol; 1975 Aug; 114(2):254-6. PubMed ID: 125803
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Androgens and prostate cancer risk.
    Wirén S; Stattin P
    Best Pract Res Clin Endocrinol Metab; 2008 Aug; 22(4):601-13. PubMed ID: 18971121
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Risk of Testosterone Flare in the Era of the Saturation Model: One More Historical Myth.
    Krakowsky Y; Morgentaler A
    Eur Urol Focus; 2019 Jan; 5(1):81-89. PubMed ID: 28753828
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.